Shalby Shares in Focus; Arm Receives US FDA Approval for Duraniom

Shalby announced that its step-down Subsidiary Advanced Technologies (SAT) Inc. secured U.S. Food and Drug Administration 510(k) Premarket Notification clearance for its Duraniom Primary Total Knee Replacement device, equipped with TiNbN coating.

FDA Approval Boosts Shalby’s Expansion

The clearance was based on safety and effectiveness data showing that the device is substantially equivalent to legally marketed predicate devices. This is a significant achievement for Shalby Ltd. as it expands its presence in the medical devices market.

Q2 FY25 Financial Highlights

The company’s net profit plunged 87.71% to ₹3.39 crore, despite a 12.42% rise in revenue from operations, which amounted to ₹267.53 crore for Q2 FY25 compared to Q2 FY24.

Profit before tax (PBT) rose 67.86% year-on-year (YoY) to ₹13.70 crore, although it showed a 54.95% decline quarter-on-quarter (QoQ). EBITDA also saw a YoY decline of 31.5%, reaching ₹39.8 crore.

Revenue from the healthcare services segment grew by 7.37% YoY to ₹239.78 crore, while revenue from the company’s implant manufacturing business surged by 89.48% YoY to ₹27.74 crore.

Shalby’s continued focus on expanding its product pipeline, enhancing operational efficiency, and reducing procurement costs is expected to further support its growth trajectory.

About Shalby

Shalby operates the largest chain of multi-specialty hospitals in Western and Central India and is known for its expertise in arthroplasty, having performed more than 145,000 joint replacements over the last 29 years. The company operates under three verticals: hospital business, Shalby Orthopedics Centre of Excellence (SOCE) franchise, and implant business.

Share Price Performance

Shalby share price traded 3.17% higher at ₹229.72 at 11:25 AM on the NSE. The stock opened at ₹227 higher than ₹226.66 at its previous close.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.